Characterizing PALB2 intragenic duplication breakpoints in a triple-negative breast cancer case using long-read sequencing

被引:0
|
作者
Ban, Iulian O. [1 ]
Chabert, Alice [1 ]
Guignard, Thomas [2 ,3 ]
Puechberty, Jacques [2 ,3 ]
Cabello-Aguilar, Simon [1 ,4 ]
Pujol, Pascal [2 ]
Vendrell, Julie A. [1 ]
Solassol, Jerome [1 ,5 ]
机构
[1] Univ Montpellier, Ctr Hosp Univ CHU Montpellier, Dept Pathol & Oncobiol, Lab Biol Tumeurs Solides, Montpellier, France
[2] Arnaud de Villeneuve Hosp, Dept Med Genet, Montpellier, France
[3] Univ Montpellier, Ctr Hosp Univ CHU Montpellier, Lab Genet Chromos, Plateforme ChromoStem, Montpellier, France
[4] Ctr Hosp Univ CHU Montpellier, Montpellier BioInformat Clin Diag MOBID, Mol Med & Genom Platform PMMG, Montpellier, France
[5] Univ Montpellier, Inst Rech Cancerol Montpellier IRCM, Inst Canc Montpellier ICM, Montpellier, France
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词
PALB2; LGR; breast cancer; long-read sequencing; molecular alteration; MECHANISMS;
D O I
10.3389/fonc.2024.1355715
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Accurate identification and characterization of Large Genomic Rearrangements (LGR), especially duplications, are crucial for precise diagnosis and risk assessment. In this report, we characterized an intragenic duplication breakpoint of PALB2 to determine its pathogenicity significance. Methods: A 52-year-old female with triple-negative breast cancer was diagnosed with a novel PALB2 LGR. An efficient and accurate methodology was applied, combining long-read sequencing and transcript analysis for the rapid characterization of the duplication. Results: Duplication of exons 5 and 6 of PALB2 was validated by transcript analysis. Long-read sequencing enabled the localization of breakpoints within Alu elements, providing insights into the mechanism of duplication via non-allelic homologous recombination. Conclusion: Using our combined methodology, we reclassified the PALB2 duplication as a pathogenic variant. This reclassification suggests a possible causative link between this specific genetic alteration and the aggressive phenotype of the patient.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Bilateral Triple-Negative Invasive Breast Cancer with a BRCA2 Mutation, and Glioblastoma: A Case Report and Literature Review
    Raufi, Ali
    Alsharedi, Mohamed
    Khelfa, Yousef
    Tirona, Maria
    JOURNAL OF BREAST CANCER, 2017, 20 (01) : 108 - 111
  • [22] Using whole exome sequencing to explore germline variation in BRCA1/BRCA2/PALB2 negative contralateral breast cancers from the Women's Environmental Cancer and Radiation Epidemiology (WECARE) study
    Larionov, A.
    Fewings, E.
    Redman, J.
    Goldgraben, M.
    Hadfield, J.
    Concannon, P.
    Bernstein, J.
    Conti, D.
    Tischkowitz, M.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 517 - 517
  • [23] Long non-coding RNA CCAT2 promotes oncogenesis in triple-negative breast cancer by regulating stemness of cancer cells
    Xu, Zhen
    Liu, Cuiui
    Zhao, Qian
    Lu, Jinhui
    Ding, Xin
    Luo, An
    He, Jia
    Wang, Guangxue
    Li, Yuan
    Cai, Zhaoqing
    Wang, Zhongrui
    Liu, Junjun
    Liu, Suling
    Li, Wenshu
    Yu, Zuoren
    PHARMACOLOGICAL RESEARCH, 2020, 152
  • [24] BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer
    F. Z. Francies
    T. Wainstein
    K. De Leeneer
    A. Cairns
    M. Murdoch
    S. Nietz
    H. Cubasch
    B. Poppe
    T. Van Maerken
    B. Crombez
    I. Coene
    R. Kerr
    J. P. Slabbert
    A. Vral
    A. Krause
    A. Baeyens
    K. B. M. Claes
    BMC Cancer, 15
  • [25] Long-term oncologic outcomes of unselected triple-negative breast cancer patients according to BRCA1/2 mutations
    Park, Woong Ki
    Chung, Soo Yeon
    Jung, You Jin
    Ha, Changhee
    Kim, Jong-Won
    Nam, Seok Jin
    Kim, Seok Won
    Yu, Jonghan
    Chae, Byung Joo
    Lee, Jeong Eon
    Kim, Sung-Won
    Ryu, Jai Min
    NPJ PRECISION ONCOLOGY, 2024, 8 (01)
  • [26] Identification of CHD4-β1 integrin axis as a prognostic marker in triple-negative breast cancer using next-generation sequencing and bioinformatics
    Fu Ou-Yang
    Pan, Mei-Ren
    Chang, Shu-Jyuan
    Wu, Chun-Chieh
    Fang, Shao-Yu
    Li, Chung-Liang
    Hou, Ming-Feng
    Luo, Chi-Wen
    LIFE SCIENCES, 2019, 238
  • [27] BRCA1, BRCA2 and PALB2 mutations and CHEK2 c. 1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer
    Francies, F. Z.
    Wainstein, T.
    De Leeneer, K.
    Cairns, A.
    Murdoch, M.
    Nietz, S.
    Cubasch, H.
    Poppe, B.
    Van Maerken, T.
    Crombez, B.
    Coene, I.
    Kerr, R.
    Slabbert, J. P.
    Vral, A.
    Krause, A.
    Baeyens, A.
    Claes, K. B. M.
    BMC CANCER, 2015, 15
  • [28] Recurrent Metaplastic Breast Cancer with Subtype Converted from Triple-Negative to HER2-Positive: A Case Report and Literature Review
    Wu, Jing
    Jin, Yudi
    Liu, Mei
    Zhu, Ningsheng
    Jing, Zhouhong
    Zeng, Xiaohua
    BREAST CANCER-TARGETS AND THERAPY, 2023, 15 : 39 - 45
  • [29] Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report
    Caputo, Roberta
    Pagliuca, Martina
    Pensabene, Matilde
    Parola, Sara
    De Laurentiis, Michelino
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [30] NGS-based targeted RNA sequencing for expression analysis of patients with triple-negative breast cancer using a modulized, 96-gene biomarker panel
    Lee, Byung-In
    Oades, Kahuku
    Vo, Lien
    Lee, Jerry
    Landers, Mark
    Wang, Yipeng
    Monforte, Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (30)